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During anti-retroviral therapy (ART) HIV-1 persists in cellular reservoirs, mostly repre-
sented by CD4+ memory T cells. Several approaches are currently being undertaken to 
develop a cure for HIV-1 infection through elimination (or reduction) of these reservoirs. 
Few studies have so far been conducted to assess the possibility of reducing the size 
of HIV-1 reservoirs through vaccination in virologically controlled HIV-1-infected children. 
We recently conducted a vaccination study with a combined hepatitis A virus (HAV) and 
hepatitis B virus (HBV) vaccine in 22 HIV-1-infected children. We assessed the size of 
the virus reservoir, measured as total HIV-1 DNA copies in blood cells, pre- and post-
vaccination. In addition, we investigated by immunostaining whether the frequencies 
of CD4+ and CD8+ T cells and parameters of immune activation and proliferation on 
these cells were modulated by vaccination. At 1 month from the last vaccination dose, 
we found that 20 out of 22 children mounted a serological response to HBV; a majority 
of children had antibodies against HAV at baseline. The number of HIV-1 DNA copies in 
blood at 1 month postvaccination was reduced in comparison to baseline although this 
reduction was not statistically significant. A significant reduction of HIV-1 DNA copies in 
blood following vaccination was found in 12 children. The frequencies of CD4+ (naïve, 
effector memory) and CD8+ (central memory) T-cell subpopulations changed following 
vaccinations and a reduction in the activation and proliferation pattern of these cells was 
also noticed. Multivariate linear regression analysis revealed that the frequency of CD8+ 
effector memory T  cells prior to vaccination was strongly predictive of the reduction 
of HIV-1 DNA copies in blood following vaccination of the 22 HIV-1-infected children. 
The results of this study suggest a beneficial effect of vaccination to reduce the size of 
virus reservoir in HIV-1-infected children receiving ART. A reduced frequency of activated 
CD4+ cells and an increase in central memory CD8+ T cells were associated with this 
finding. Further studies should assess whether vaccination is a possible tool to reduce 
HIV-1 reservoirs.
Keywords: vaccination, hepatitis B virus, hepatitis a virus, hiV-1 reservoirs, anti-retroviral therapy, immune 
activation, T-cell proliferation
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inTrODUcTiOn
Anti-retroviral therapy (ART) provided to HIV-1-infected patients 
infected with human immunodeficiency virus type 1 (HIV-1) 
does not lead to virus eradication as HIV-1 persists in memory 
CD4+ T cells which represent a stable and long-lived reservoir 
for this infection (1, 2). At present, approximately 40 million 
people live with HIV-1 infection and this number will increase as 
a result of new infections and ART scale-up limiting mortality. As 
HIV-1 patients need to receive life-long treatment, the economic 
burden of life-long ART for countries highly affected by HIV-1 is 
immense. The elimination of HIV-1 reservoirs could lead to cure 
of HIV-1 infection; accordingly, novel targets for curing HIV-1 
infection through reactivation and elimination of virus reservoirs 
are under investigation. A possible approach is the “shock and kill” 
(3) strategy designed to induce the expression of HIV-1 proteins 
in infected host cells (“shock”) thereby enabling the immune sys-
tem, primarily CD8+ cytotoxic T cells, to identify and clear these 
cells (“kill”). Histone deacetylases inhibitors (HDACis) were the 
first candidate compounds investigated as possible HIV-1 latency 
reversing agents. Clinical studies conducted with HDACis in 
HIV-1-infected patients have shown that HDACis may enhance 
HIV-1 transcription (4–8) although a significant decrease of virus 
reservoirs was not observed. A number of different compounds 
have later been considered, but the success in reducing the virus 
reservoir is still limited (9). Thus, additional approaches need 
to be developed and evaluated to reactivate and eliminate latent 
HIV-1 infection. Until new medicines will be available for cur-
ing HIV-1 infection it is however important to provide ART to 
HIV-1-infected patients as early as possible, ideally already at the 
phase of primary HIV-1 infection, as early ART administration 
reduces inflammation linked to HIV-1 pathogenesis and confines 
the size of HIV-1 reservoirs (10).
The possibility of developing an HIV-1 cure in the context of 
pediatric HIV-1 infection is also under debate (11). One of the 
obvious features of pediatric infection which may be advanta-
geous in the context of HIV-1 cure is that HIV-1 infection can 
be diagnosed in infants born to HIV-1-infected mothers within 
hours from birth thus facilitating early ART intervention. 
However, when ART was discontinued in a group of HIV-1-
infected children in South Africa who were provided ART from 
a median age of 7  weeks (12), only one child presented with 
undetectable virus in absence of drugs, whereas all other children 
presented with virus rebound (13). An additional recent publica-
tion reported HIV-1 virological remission in an HIV-1-infected 
teenager who started ART before 6 months of age (14); once this 
patient discontinued ART, at approximately 6 years of age, HIV 
RNA remained <50 copies/mL for approximately 12 years and 
CD4+ T-cell counts were stable (14).
Several phenotypic dysfunctions occur in the total bulk of 
T cells, HIV-1 specific and non-specific, during HIV-1 infection. 
T  cells are characterized by the high expression of activation 
markers, including CD38 and HLA-DR, which are independent 
predictors of CD4+ T-cell decline and progression to AIDS (15). 
In HIV-1-infected children, the expression of activation markers 
was reduced after 44 weeks of ART (16). Divergent results have, 
however, also been presented on persistent CD8+ T-cell activation 
in HIV-1-infected youth after 48 weeks of ART (17). These find-
ings suggest that strategies to eliminate HIV-1 reservoirs may also 
include strengthening CD8+ T-cell responses in HIV-1-infected 
individuals; a characteristic feature of HIV-1 pathogenesis is a 
dysfunctional pool of CD8+ T cells, considered to be one of the 
causes for establishment of chronic HIV-1 infection [reviewed 
in Ref. (18)].
The influence of vaccination in affecting the size of HIV-1 
reservoirs has been previously evaluated in the context of influ-
enza vaccination in cohorts of adult HIV-1-infected individuals 
(19–21). Whether vaccinations provided during childhood may 
be useful tools to reduce the size of HIV-1 reservoir in HIV-
1-infected children has not been previously evaluated; this is 
important to study as childhood vaccinations are provided to 
the majority of infants worldwide. Vaccination against hepatitis 
B virus (HBV) has been introduced in many countries at birth; 
within the frame of a recent vaccination study against combined 
hepatitis A virus (HAV) and HBV infections in young HIV-1-
infected children who had received ART for a prolonged period 
of time, we assessed whether the size of the virus reservoir and 
indicators of CD4+ and CD8+ T-cell function were modulated 
by HBV vaccination. In individuals naturally infected with HBV, 
the strength of CD8+ T-cell responses to the virus determines 
whether the infected individual clears the infection or HBV 
establishes a persistent infection (22, 23). In addition, a broad 
recognition range of HBV epitopes by CD4+ and CD8+ T cells is 
a prognostic marker for likelihood of resolving acute HBV infec-
tion (24, 25). Virological markers of HBV-related diseases have 
recently been associated with HLA-A genotype, further support-
ing the important role of CD8+ T cells in controlling natural HBV 
infection (26). MHC class-I-restricted HBV epitopes derived 
from several HBV proteins, including the HB antigen, have been 
shown to activate CD8+ T-cell responses (27).
MaTerials anD MeThODs
Patient cohorts and hBV Vaccination 
schedule
Twenty-two HIV-1-infected children (8 males and 14 females) 
with a median age of 15  years (range 6–18  years) followed at 
Karolinska University Hospital were included in the vaccination 
study. For 20 of the children, a vertical route of transmission was 
confirmed; the route of transmission was unknown for two of the 
children. At the time of the first vaccination dose, the children had 
received ART for a median period of 7.2 years and their median 
CD4+ T-cell count was 715 cells/μL. Viral load was undetectable 
(<20 copies/mL) in plasma of 18 (81.8%) children.
HIV-1-infected children were vaccinated with Twinrix® 
(GlaxoSmithKline AB), a combination vaccine against HAV 
(inactivated) and HBV (recombinant); the children received 
three doses of vaccine with 4-week intervals between the doses. 
According to clinical records, the children were not previously 
vaccinated for HBV. A blood sample was collected prior to vac-
cination and at 1 month after completed vaccination. Peripheral 
blood mononuclear cells (PBMCs) were isolated using Ficoll 
gradient centrifugation (Lymphoprep, Axis-Shield Poc AS, Oslo, 
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Norway) and stored in liquid nitrogen at −160°C for later use. 
Serum specimens were stored at −80°C until further analyses 
were conducted.
The study was carried out in accordance with the recom-
mendations of the ethical committee at the Karolinska Institutet 
(Protocol no. Dnr 2013/774-31/1). Written informed consent was 
obtained, in accordance with the Declaration of Helsinki, from 
the parents of study participants following a clear explanation of 
the study purpose, benefit and possible discomfort.
Determination of Plasma anti-hBV and 
anti-haV antibodies
The anti-HBs Monolisa Anti-HBs Plus assay (Bio-Rad, France) 
was used to measure the plasma levels of anti-HBV vaccine anti-
bodies. The assay was run according to the instruction provided 
by the manufacturer. The cutoff value for samples to be consid-
ered positive for the presence of antibodies to the HBV vaccine 
is 10 IU/L (1 log IU/L). All samples and standards were tested in 
duplicate. The OD values were converted to concentrations using 
Microplate manager version 6 (Bio-Rad, CA, USA).
Total (IgG and IgM) HAV antibodies, and IgM on a separate 
test, were measured by electro-chemiluminescence immunoassay 
(ECLIA) (Roche, Basel, Switzerland). Samples were considered 
positive for total anti-HAV Igs (IgG and IgM) antibodies when 
the measurements showed values >20 IU/L.
Measurement of Total PBMc hiV-1 Dna
The PBMC DNA was obtained by manual extraction with the 
High Pure Viral Nucleic Acid Kit (Roche, Basel, Switzerland). 
Total PBMC HIV-1 DNA was quantified by using a homemade 
Taqman real-time assay targeting a highly conserved region of the 
long terminal repeat gene (28).
immunostainings of T-cell subpopulations
Peripheral blood mononuclear cells obtained pre- and postvac-
cination were thawed and stained simultaneously to avoid run-
to-run variation. To measure the frequency of different T-cell 
populations and immune activation of T  cells, the following 
monoclonal antibodies were used: anti-CD3 (UCHT1), anti-CD4 
(RPA-T4), anti-CD8 (RPA-T8), anti-CD45RA (HI100), anti-
CCR7 (3D12), anti-CD38 (HIT2), and anti-HLA-DR (G46-6) all 
from BD Biosciences (CA, USA). To assess T-cell proliferation, 
Ki67 expression was measured: for this purpose, PBMCs were 
fixed, permeabilized using the BD Cytofix/Cytoperm kit, and 
stained with anti-Ki67 (MIB-1) from Dako (Glostrup, Denmark). 
LIVE/DEAD Fixable Near-IR kit (Life Technologies Europe BV, 
Stockholm, Sweden) was used to exclude dead cells from the 
analyses. Stained cells were washed with phosphate-buffered 
saline (PBS) before being fixed in 2% paraformaldehyde. All anti-
bodies were used at the concentrations determined after titration 
experiments. Matched isotype controls or fluorescence minus 
one (FMO) were used to set the gating strategies. Fluorescence 
intensities were measured with LSRII (BD) and data were ana-
lyzed using FlowJo, version 9.4.11 (Tree Star, OR, USA).
T-cell subsets were gated out using the following antibody com-
binations for CD4+ T-cell subsets: total CD4+ T cells (CD3+ CD4+ 
CD8−), CD4+ naïve (CD3+ CD4+ CD8− CD45RA+ CCR7+), 
CD4+ central memory (CM) (CD3+ CD4+ CD8− CD45RA− 
CCR7+), CD4+ effector memory (EM) (CD3+ CD4+ CD8− 
CD45RA− CCR7−), and CD4+ terminally differentiated effector 
memory (TEMRA) (CD3+ CD4+ CD8− CD45RA+ CCR7−). 
CD8+ T-cell subsets were defined as total CD8+ T cells (CD3+ 
CD4− CD8+), CD8+ naïve (CD3+ CD4− CD8+ CD45RA+ 
CCR7+), CD8+ CM (CD3+ CD4− CD8+ CD45RA− CCR7+), 
CD8+ EM (CD3+ CD4− CD8+ CD45RA− CCR7−), and CD8+ 
TEMRA cells (CD3+ CD4− CD8+ CD45RA+ CCR7−).
statistical analysis
Data were analyzed using GraphPad prism version 7 (La Jolla, CA, 
USA). Paired T-test was used to analyze clinical and immunologi-
cal parameters. A value of p < 0.05 was considered statistically 
significant.
Linear regression analysis was performed to identify clinical and 
immunological parameters as potential predictors of the change in 
HIV-1 DNA copies between baseline (BL) and 1 month postvac-
cination (M1). Due to the small sample size and the large number 
of variables showing association with the dependent variable at 
univariate analysis, only parameters scored as significant at p < 0.01 
level at univariate analysis were selected for stepwise multivariate 
linear regression analysis. In the first step, CD4+ and CD8+ T cells 
and subsets were included. In the second step, the expression of 
activation markers (CD38 and HLA-DR) among CD4+ and CD8+ 
T cells and subsets were added; the expression of Ki67 proliferation 
marker among CD4+ and CD8+ T cells and subsets were entered 
in the third step. The number of HIV-1 DNA copies at BL were 
added in the fourth step. The values of p < 0.05 were considered 
statistically significant. Linear regression analysis was performed 
using SPSS version 25 (IBM Corp, Armonk, NY, USA).
resUlTs
antibody response to hBV Vaccine and 
size of the Virus reservoir
Prior to vaccination, none of the 22 HIV-1-infected children 
included in the study displayed measurable levels of antibody 
to HBsAg (Figure 1A) and all samples scored below the cutoff 
value of 1 log IU/L. At 1 month from the last vaccination 20 of 
the 22 children had detectable antibody titers (>1 log IU/L) to 
HBsAg; the median logarithmic titer of anti-HBsAg antibody was 
2.48 IU/L (range 0.01–3.50). The clinical characteristics of the 
individuals included in the study are shown in Table 1.
The analysis of total anti-HAV Igs (IgG and IgM) antibodies 
revealed that 12 of the 22 children included in the study had antibod-
ies against HAV in serum prior to vaccination; all 22 children were 
positive for HAV total Ig following vaccination (data not shown). 
As the anti-HAV IgM test scored negative pre- and postvaccination, 
we concluded that 12 of the patients carried anti-HAV IgG at BL 
and all 22 at 1 month postvaccination. As it is not clear whether 
the anti-HAV antibodies detected at BL were mounted as results of 
previous exposure, this parameter was not further evaluated.
The size of the virus reservoir, expressed as HIV-1 DNA 
copies/106 PBMCs, was measured prior to vaccination and at 
TaBle 1 | Clinical characteristics of HIV-1-infected children included in the study.
characteristic hiV-1-infected 
baseline
hiV-1-infected 
M1
Age (years); median (range) 15 (6–18) Idem
Gender
Male 8 (36.4%)
Female 14 (63.6%) Idem
Transmission route
Vertical 20 (90.9%)
Other/unknown 2 (9.1%) Idem
Years on ART: median (range) 7.2 (0.73–17.46) Idem
CD4 count (cells/mL): median (range) 715 (250–1,360) 765 (240–1,390)
Viral load (RNA copies/mL)
Undetectable 18 (81.8%) 20 (90.9%)
44, 155, 749, 96,500 4 (18.2%) –
53, 511 – 2 (9.1%)
HIV DNA copies/106 PBMC (log): mean 
(range)
3.35 (2.19–5.10) 3.23 (2.31–4.40) 
Undetectable viral load = <20 copies/mL.
FigUre 1 | Antibody titers to hepatitis B virus vaccine and HIV-1 DNA 
copies in peripheral blood mononuclear cells (PBMCs) of HIV-1-infected 
children pre-vaccination and postvaccination. Antibodies to the HBsAg were 
detected in plasma (a) and HIV-1 DNA copies/106 PBMCs were measured in 
PBMCs (B) from 22 HIV-1-infected children pre-vaccination and at 1 month 
postvaccination. ns, not significant; BL, baseline; M1, month 1.
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1 month from the last vaccination (Figure  1B). The median 
logarithmic value (range) of HIV-1 DNA copies in blood cells 
of HIV-1-infected children was 3.29 (2.19–5.10) at BL and 3.10 
(2.31–4.40) at 1 month postvaccination. The decline in number of 
HIV-1 DNA copies detected at 1 month postvaccination was not 
statistically significant. Likewise, no correlation could be found 
between the levels of anti-HBsAg antibodies at 1 month from last 
vaccination and the size of virus reservoir at either BL or 1 month 
postvaccination (results not shown).
Frequency of Blood cD4+ and cD8+ 
T-cell subpopulations and expression of 
activation Markers in Vaccinated 
individuals
The gating strategy for characterization of CD4+ and CD8+ 
T-cell subpopulations is shown in Figure  2. We analyzed the 
frequency of CD4+ and CD8+ T-cell subpopulations in blood 
of HIV-1-infected children prior to vaccination and at 1 month 
from completed vaccination and also assessed the expression of 
activation markers CD38 and HLA-DR on CD4+ and CD8+ 
subpopulations.
The frequency of CD4+ T-cell subpopulations and the 
expression of activation markers on these cells are shown in 
Figures 3A–C. For some of the analyzed subpopulations, there 
was a significant difference between the samples collected at BL 
and at 1 month postvaccination. The frequency of naïve CD4+ 
T cells was reduced at month 1 from vaccination (mean value BL 
50.2 versus M1 46.9; p < 0.01); the opposite trend was noticed for 
EM CD4+ T cells which frequency increased at 1 month from 
vaccination (mean value BL 23.3 versus M1 25.3; p < 0.05). The 
frequency of CM CD4+ T cells expressing the activation marker 
CD38 was significantly reduced at 1 month (mean value BL 11.4 
versus M1 9.0; p < 0.01) (Figure 3B).
The frequency of CM CD8+ T cells (Figures 3D–F) signifi-
cantly increased at month 1 (mean value BL 5.2 versus M1 6.1; 
p < 0.01). A decline in the frequency of cells expressing the activa-
tion marker HLA-DR was noticed among total (mean value BL 
13.6 versus M1 11.0; p < 0.05), CM (mean value BL 25.7 versus 
M1 20; p < 0.05), and EM (mean value BL 27.4 versus M1 22.0; 
p < 0.01) CD8+ T cells.
Abnormal proliferation of T cells is a sign of immunopathol-
ogy during HIV-1 infection. In order to assess the degree of 
proliferation of CD4+ and CD8+ T-cell subpopulations, we 
measured the frequency of cells expressing the Ki67 proliferation 
marker. A decline in the frequency of cells expressing Ki67 was 
noticed for CM (mean value BL 1.96 versus M1 1.3; p < 0.01) and 
EM (mean value BL 2.8 versus M1 1.8; p < 0.01) CD4+ T cells 
(Figure  4A). A clear decline of cells expressing Ki67 was also 
noticed among CD8+ T cells at month 1 reaching a statistically 
significant difference for total (mean value BL 0.9 versus M1 0.5; 
p < 0.05), EM (mean value BL 2.5 versus M1 1.6; p < 0.01), and 
TEMRA (mean value BL 1.36 versus M1 1.0; p <  0.05) CD8+ 
T cells (Figure 4B).
Factors Predictive of changes in hiV-1 
Dna copies following Vaccination
In order to understand if changes in HIV-1 DNA copies post-
vaccination could be predicted by clinical and immunological 
parameters, we conducted linear regression analysis. At univari-
ate analysis, age, CD4+ T-cell count, and length of ART did not 
significantly predict a change in HIV-1 DNA copies following 
vaccination. By contrast, BL HIV-1 DNA levels and a number 
of immunologic markers were significantly predictive of HIV-1 
DNA changes (Table 2).
When the significant variables were processed through 
stepwise multivariate linear regression analysis, five models were 
generated (Table  3) showing significant predictive value for 
the frequency of CD8+ EM T cells, CD38+ EM CD8+ T cells, 
HLA-DR+ CM CD8+ T cells, Ki67+ CD8+ T cells, and HIV-1 
DNA copies prior to vaccination. In model 1, a high-regression 
coefficient was found for CD8+ EM T cells which explained 75% 
of the variance for the decline of HIV-1 DNA postvaccination. 
FigUre 2 | Gating strategy for subpopulations of CD4+ and CD8+ T cells. After exclusion of dead cells and doublets, total T cells were identified by CD3 surface 
expression. Gated CD3+ T cells were divided into CD4+ and CD8+ T-cell subsets. The CD4+ and CD8+ T-cell subpopulations [naive, EM, CM, TEMRA] were 
identified by CD45RA and CCR7 expression.
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In the final model 5, the frequency of Ki67+ CD8+ T cells and 
HIV-1 DNA copies prior to vaccination retained the maximal 
predictive value; however, these variables only contributed with 
5% of the variance for the decline of HIV-1 DNA postvaccination.
In order to further dissect whether HBV vaccination had an 
impact on the size of the virus reservoir, we also analyzed the num-
ber of HIV-1 DNA copies by separating patients in three groups 
(Figure 5) including the following: (i) children who displayed a 
significantly reduced (>10% variation) number of HIV-1 DNA 
copies at 1 month from last vaccination (median copies 3.25) as 
compared with BL logarithmic value (median 3.63, p < 0.001); 
(ii) children who displayed minor variation (<10%) between the 
two time points (month 1 copies 3.03 versus copies at BL 3.06); 
(iii) children who showed an increased (>10% variation) number 
FigUre 4 | Frequency of Ki67+ CD4+ and CD8+ T-cell subpopulations. The frequency of Ki67+ CD4+ (a) and CD8+ (B) T-cell subpopulations (naïve, CM, EM, 
and TEMRA) were measured in blood specimens of 22 HIV-1-infected children at baseline and 1 month postvaccination. *p < 0.05; **p < 0.01; ns, not significant; 
BL, baseline; M1, month 1.
FigUre 3 | Frequency of CD4+ and CD8+ T-cell subpopulations and of T cells expressing the CD38 and HLA-DR activation markers. CD4+ T cells were divided 
into naïve, CM, EM, and TEMRA. The frequencies of CD4+ T-cell subpopulations (a) were assessed at BL and 1 month postvaccination. The frequency of CD4+ 
T-cell subpopulations expressing CD38 (B) and HLA-DR (c) were also measured. The frequency of CD8+ T-cell subpopulations and of CD8+ T cells expressing 
CD38 and HLA-DR are shown in panels (D–F). *p < 0.05; **p < 0.01; ns, not significant; BL, baseline; M1, month 1.
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of HIV-1 DNA copies at 1 month (median 3.35) as compared 
with BL (median 2.84). The three groups were on a median ART 
length of 7.5 (decrease), 6.4 (stable), and 7.3 (increase) years. As 
shown in Figure 5A, following vaccination a decreased level of 
HIV-1 DNA copies was found in 12 children; the level of HIV-1 
DNA copies remained stable (or unchanged) in five children and 
increased in five children. The number of HIV-1 DNA copies was 
significantly higher prior to vaccination in the group “decrease” 
as compared with the group “increase.”
We plotted the frequency of T-cell subpopulations and expres-
sion of activation (CD38 and HLA-DR) and proliferation (Ki67) 
markers according to whether the children displayed a decrease, 
an increase, or a similar value of HIV-1 DNA copies in PBMCs at 1 
month postvaccination compared with BL. Significant differences 
were found for four parameters (Figures 5B–E). The frequency of 
naïve CD4+ T cells was significantly lower in the patients display-
ing a decrease of DNA copies at 1 month postvaccination and a 
decline in Ki67+ expressing cells was also observed among CM 
TaBle 2 | Univariate linear regression analysis between changes in HIV-1 DNA 
copies [baseline minus 1 month from vaccination (dependent variable)] and 
immunological and clinical parameters (independent variables).
Model Unstandardized 
coefficients
standardized 
coefficients
t p-Value
B Beta
CD4+ −1,037.17 −0.53 −2.77 0.012
CD38+ CD4+ 2,550.75 0.22 1.02 ns
HLA-DR+ CD4+ 5,332.50 0.49 2.49 0.022
Naïve CD4+ −521.33 −0.31 −1.44 ns 
CD38+ naïve CD4+ −941.69 −0.05 −0.23 ns 
HLA-DR+ naïve CD4+ −2,283.45 −0.13 −0.56 ns 
CM CD4+ −322.40 −0.08 −0.37 ns 
CD38+ CM CD4+ 941.17 0.17 0.79 ns 
HLA-DR+ CM CD4+ 3,691.52 0.47 2.39 0.027
EM CD4+ 1,136.95 0.47 2.38 0.027
CD38+ EM CD4+ 1,714.14 0.30 1.39 ns 
HLA-DR+ EM CD4+ 127.13 0.03 0.13 ns 
TEMRA CD4+ 3,111.49 0.14 0.62 ns 
CD38+ TEMRA CD4+ −108.46 −0.02 −0.07 ns 
HLA-DR+ TEMRA 
CD4+
852.69 0.14 0.62 ns 
CD8+ 1,247.43 0.57 3.10 0.006
CD38+ CD8+ 5,686.74 0.82 6.38 0.000
HLA-DR+ CD8+ 1,786.08 0.78 5.57 0.000
Naïve CD8+ −638.82 −0.50 −2.60 0.017
CD38+ naïve CD8+ 1,785.66 0.08 0.36 ns 
HLA-DR+ naïve CD8+ 2,400.15 0.19 0.85 ns 
CM CD8+ 2,385.17 0.20 0.92 ns 
CD38+ CM CD8+ 2,828.93 0.65 3.84 0.001
HLA-DR+ CM CD8+ 1,472.30 0.68 4.11 0.001
EM CD8+ 1,565.03 0.87 7.75 0.000
CD38+ EM CD8+ 4,258.01 0.66 3.92 0.001
HLA-DR+ EM CD8+ 1,391.69 0.71 4.48 0.000
TEMRA CD8+ −214.19 −0.15 −0.66 ns 
CD38+ TEMRA CD8+ 5,343.73 0.48 2.42 0.025
HLA-DR+ TEMRA 
CD8+
654.77 0.35 1.66 ns 
KI-67+ CD4+ 14,341.00 0.44 2.20 0.040
KI-67+ naïve CD4+ 20,125.01 0.41 2.01 ns 
KI-67+ CM CD4+ 6,922.45 0.38 1.83 ns 
KI-67+ EM CD4+ 3,022.22 0.23 1.04 ns 
KI-67+ TEMRA CD4+ 7,480.53 0.38 1.84 ns 
KI-67+ CD8+ 22,851.56 0.94 12.34 0.000
KI-67+ naïve CD8+ 26,084.09 0.33 1.56 ns 
KI-67+ CM CD8+ 5,046.98 0.40 1.97 ns 
KI-67+ EM CD8+ 10,504.31 0.56 3.05 0.006
KI-67+ TEMRA CD8+ 6,850.65 0.20 0.91 ns
Age 1,463.11 0.20 0.92 ns
DNA_BL 0.87 0.98 23.89 0.000
CD4_BL −41.39 −0.43 −2.12 ns
Years ART −377.89 −0.07 −0.31 ns
ns, non-significant; significant values <0.01.
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and EM CD4+ T cells in this group of patients (Figures 5B–D). 
On the other hand, the frequency of CM CD8+ T cells was higher 
at 1 month postvaccination in the children displaying a decrease 
of DNA copies at 1 month postvaccination (Figure 5E).
DiscUssiOn
Following vaccination with a mixed HAV and HBV vaccine in 22 
HIV-1-infected children, we noticed a decline of total HIV-1 DNA 
in PBMCs; this decline, detected at 1 month postvaccination, was 
not statistically significant. In 54% of the HIV-1-infected children, 
however, a reduction in the number of HIV-1 DNA copies in 
PBMCs following vaccination was observed. The decline of HIV-1 
DNA copies was detected in children presenting with a reduced 
frequency of proliferating CM CD4+ T cells and an increased fre-
quency of CM CD8+ T cells following vaccination; this result may 
suggest that the declined levels of HIV-1 DNA copies in blood of 
HIV-1-infected children vaccinated with HAV and HBV may be 
due to a reduction of HIV-1 target cells in the presence of a larger 
number of CD8+ T cells flushing HIV-1-infected cells.
Previous studies have analyzed the possibility of affecting the 
size of the virus reservoir through influenza vaccination in cohorts 
of adult HIV-1-infected individuals. In a study conducted prior to 
ART introduction, major changes in the levels of pro-viral DNA in 
PBMCs could not be detected following vaccination; the levels of 
peak PBMC viral RNA, however, increased significantly following 
vaccination (19). A study conducted in 19 HIV-1-infected patients 
on ART showed that a transient elevation of plasma HIV-1 RNA 
levels occurred in patients with undetectable HIV-1 RNA follow-
ing vaccination; an even more significant HIV-1 RNA increase 
was detected in patients presenting with detectable HIV-1 RNA at 
BL (20). Interestingly, in the latter study, the levels of HIV-1 DNA 
decreased in patients presenting with <400 HIV-1 RNA copies at 
BL (20); this result may indicate that, in the presence of effective 
ART, vaccination may reduce HIV-1-associated immune activa-
tion and lead to reduced HIV-1 replication. A very recent study 
conducted in HIV-1-infected women reported no changes in 
HIV-1 DNA concentration following influenza vaccination and, 
in addition, analysis of HIV-1 sequences did not suggest HIV-1 
replication taking place as a result of vaccination (21).
Several measurements, including the copies of integrated 
HIV-1 DNA, can be used to evaluate the size of the virus reservoir 
(29); the measure of total HIV-1 DNA in PBMCs used in the 
present paper has been shown to correlate well with the induc-
ible HIV-1 reservoir (30). Which of the components included 
in the vaccine can be correlated to the beneficial effect on the 
virus reservoir was not studied. The vaccine used in this study is a 
combination of inactivated HAV and recombinant HBV antigens 
and contains also a proportion of aluminum adjuvants provided 
as aluminum phosphate and hydroxide. It is obviously important 
to identify which vaccine components may have an impact on 
the size of the virus reservoir and future clinical studies should 
be designed to address this question. It is not easy to envisage 
why the vaccine used in this study should work to reduce the size 
of the virus reservoir in some patients when vaccines to other 
antigens, including influenza, did not induce any reduction in the 
size of virus reservoir. It cannot be excluded that the reduction 
of HIV-1 DNA upon vaccination noticed in 54% of the children 
may be due to reasons other than vaccination, e.g., ART treat-
ment; further studies on this topic should therefore include a 
group of non-vaccinated, HIV-1-infected children, with similar 
length of treatment as the vaccinated group. Recent publications 
(31, 32) have provided a detailed picture of HIV-1 DNA decay 
dynamics in blood over time in both adults and children infected 
with HIV-1. The study in adults (31) showed that HIV-1 DNA 
decay comprises three different phases: phase I, from 0 to 1 year 
TaBle 3 | Stepwise multivariate linear regression analysis between changes in HIV-1 DNA copies [baseline minus 1 month from vaccination (dependent variable)] and 
clinical and immunological parameters (independent variables).
Model Unstandardized 
coefficients
standardized 
coefficients
t sig. R2 R2 change adjusted R2 F change (significance of 
F change)
B Beta
1 EM CD8+ 1,565.03 0.866 7.75 0.000 0.750 0.750 0.738 60.10***
2 EM CD8+ 1,294.63 0.717 6.22 0.000 0.814 0.063 0.794 6.45*
CD38+ EM CD8+ 1,891.26 0.293 2.54 0.020
3 EM CD8+ 947.48 0.524 3.92 0.001 0.856 0.042 0.832 5.23*
CD38+ EM CD8+ 2,146.67 0.332 3.15 0.006
HLA-DR+ CM CD8+ 586.97 0.270 2.29 0.034
4 EM CD8+ 396.01 0.219 1.87 0.079 0.932 0.076 0.916 19.14***
CD38+ EM CD8+ 974.18 0.151 1.77 0.095
HLA-DR+ CM CD8+ 361.01 0.166 1.92 0.072
Ki67+ CD8+ 13,719.01 0.564 4.38 0.000
5 EM CD8+ 179.14 0.099 1.51 0.152 0.981 0.049 0.976 42.58***
CD38+ EM CD8+ 209.73 0.032 0.66 0.520
HLA-DR+ CM CD8+ −76.80 −0.035 −0.63 0.537
Ki67+ CD8+ 4,976.75 0.205 2.31 0.035
HIV-1 DNA copies 0.64 0.718 6.53 0.000
*<0.05; ***<0.001.
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of ART, with a significant decay (approximately 1 log); phase II, 
from 1 to 4 years of ART, with <0.5 log decay; and phase III, after 
4 years of ART, where the decay is minimal. In the study address-
ing HIV-1 DNA decay in the blood of HIV-1-infected children 
(32), patients were followed up to 4 years from ART initiation: a 
highly significant decay (1 log) was noticed during the first year 
of ART and the difference in HIV-1 DNA copies between 1 and 
4 years of ART started to reach a plateau (0.2 log difference). In 
our cohort, at the time of vaccination, the children had been on 
ART for already a median time of approximately 7  years; this 
makes it possible that the reduction of HIV-1 DNA copies in 
blood noticed in some of the HIV-1-infected children may be 
due to effects promoted from vaccination An additional study, 
addressing long- and short-term dynamics of HIV-1 reservoir in 
peripheral blood, also reported that the copies of HIV-1 DNA 
remained stable over time (30).
The efficacy of HBV vaccines depends on the establishment 
of long-term immunological memory; the development of anti-
bodies to protein-based HBV vaccine is the important hallmark 
for protection although HBV-DNA-based vaccines have been 
shown to stimulate CD8+ CTL cells (33, 34). It is likely that a 
well-controlled clinical picture of HIV-1 infection and sustained 
virological remission play an important role in decreasing the 
size of HIV-1 reservoir in vaccinated children. It is important to 
notice that previous studies addressing the potential role of vacci-
nation in affecting the size of HIV-1 reservoirs were conducted in 
adults and this is, to the best of our knowledge, the first attempt to 
study whether vaccination has a role in modifying the dynamics 
of HIV-1 DNA in PBMCs of infected children.
Abnormal immune activation is a driving force for HIV-1 
pathogenesis; prior to the introduction of ART in HIV-1 clinical 
practice, both CD4+ and CD8+ T cells were characterized by the 
high expression of surface activation markers, including CD38 
and HLA-DR (35). ART introduction during the chronic phase 
of HIV-1 infection has reduced, but not normalized, abnormal 
features of immune activation and this ameliorated picture has 
also been detected in HIV-1-infected children treated with ART 
(36). In order to preserve immune competence and confine 
inflammation related to chronic HIV-1 infection, WHO recently 
recommended that ART should be initiated in HIV-1-infected 
children from birth and in adults as soon as infection is detected, 
ideally already during the phase of primary HIV-1 infection. To 
which extent ART initiation in the early phase of HIV-1 infection 
will prevent the establishment of abnormal immune activation 
is still an intensive topic of investigation and a recent study sug-
gested that low levels of immune activation and inflammation 
may persist even when ART is initiated during the acute phase 
of HIV-1 infection (37). We recently reported that an equivalent 
abnormal expression of activation (HLA-DR and CD38 on CD4+ 
T cells) and terminal differentiation (CD127 on CD8+ T cells) 
markers were present on T  cells from HIV-1-infected patients 
who initiated ART either during the primary or chronic phase 
of infection (38); the size of total HIV-1 DNA copies in blood 
of patients who initiated ART during primary infection was, 
however, lower compared with patients who initiated ART during 
chronic infection. Only a minority of the children included in our 
cohort had been treated from birth.
We noticed a significant fluctuation in terms of T-cell popula-
tions following vaccination: naïve CD4+ T cells were significantly 
reduced whereas the frequency of CM CD8+ T cells was signifi-
cantly increased. The frequency of cells expressing parameters of 
immune activation and proliferation was reduced postvaccina-
tion with a decline in the frequency of activated CD38+ CM 
CD4+ T cells, HLA-DR+ CM and EM CD8+ T cells, Ki67+ CM 
and EM CD4+ T cells, and Ki67+ EM and TEMRA CD8+ T cells. 
CM CD4+ T  cells are considered to be one of the major size 
HIV-1 reservoirs (39); it is noteworthy that vaccination led to a 
reduction in the frequency of CD38+ CM CD4+ T cells and that 
proliferating Ki67+ cells were reduced among both CM and EM 
CD4+ T cells. All in all, a reduction in the T-cell activation profile 
FigUre 5 | Frequency of T-cell subpopulations according to changes in HIV-1 DNA copies at 1 month from vaccination. HIV-1 DNA copies/106 peripheral blood 
mononuclear cells (PBMCs) were measured in PBMCs from 22 HIV-1-infected children (a). In the group “decrease,” 12 children are included who displayed >10% 
decrease in the number of HIV-1 DNA copies at 1 month from last vaccination as compared with BL value; in the group “stable,” 5 children who displayed minor 
variations (<10%) between the two time points are included; in the group “increase,” 5 children were included showing an increased (>10% variation) number of 
HIV-1 DNA copies at 1 month. In the three groups of children divided according to whether the HIV-1 DNA copies in PBMCs decreased, remained stable or 
increased at month 1 from vaccination we found that the frequency of naïve CD4+ T cells (B), Ki67+ CM CD4+ T cells (c) and Ki67+ EM CD4+ T cells (D) was 
reduced in the “decrease” group; in the same group an increase in CM CD8+ T cells (e) was revealed at month 1. BL, baseline; M1, month 1. *p < 0.05; 
****p < 0.001.
9
Bekele et al. HBV Vaccination and HIV-1 Reservoirs
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1966
was found following vaccination in these virologically controlled 
HIV-1-infected children.
We also analyzed whether significant changes in the frequency 
of T-cell subpopulations and cells expressing activation and 
proliferation markers could be noticed in relation to the decrease 
of HIV-1 DNA copies in PBMCs following vaccination. It is of 
interest that in the group of children where a significant reduc-
tion of HIV-1 DNA copies was found following vaccination, 
there was an increase in CM CD8+ T cells and a reduction in 
the expression of Ki67 in CM and EM CD4+ T cells. According 
to this result it is likely that ameliorated immunological condi-
tions, including the increased number of memory CD8+ T cells, 
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cells devoted to the control of infections, may lead to a reduced 
amount of HIV-1 DNA copies in PBMCs. This result may reflect 
direct killing of infected cells due to increased frequency of 
CD8+ T cells or a dependency of the virus reservoir persistence 
on parameters of immune activation and proliferation. In this 
respect it is interesting that Hurst (40) showed that the expression 
of HLA-DR and CD38 on CD4+ and CD8+ T cells correlated 
with the size of total HIV-1 DNA at primary HIV-1 infection. 
Although it is not completely understood how HIV-1 reservoirs 
are maintained in HIV-1-infected patients during ART, a recent 
study suggested that these reservoirs are in part sustained by 
homeostatic cell proliferation (41). Thus, it appears relevant that 
the reduction of virus reservoir upon vaccination in our study 
occurs in parallel with the frequency of activated, proliferating 
CM CD4+ T cells.
In the group of 22 children in our study, the frequency of CD8+ 
EM T  cells was an efficient predictor of the decline in HIV-1 
DNA copies postvaccination using multivariate linear regression 
analysis. A study conducted in rhesus monkeys infected with 
simian immunodeficiency virus (SIV) showed that a strong viral 
inhibition activity was associated with EM CD8+ T cells rather 
than CM CD8+ T cells, high degranulation activity and perforin 
production by EM CD8+ T cells (42). Experiments conducted 
with sorted CD8+ T cells from elite controllers cocultured with 
HIV-1-infected CD4+ T cells revealed that EM CD8+ T cells had 
a high viral inhibition capacity in culture (43).
The results obtained in this study are important to elucidate 
which immunological markers can define ART-treated children 
where the HIV-1 reservoir can be reduced following a combined 
HAV and HBV vaccination. A follow-up by additional vaccina-
tion studies conducted in HIV-1-infected adults and children 
is important taking in consideration the time of ART initiation 
and other parameters currently utilized to evaluate the size of the 
virus reservoir (29).
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